StemCell Therapy

When people with diabetes are discharged from hospital researchers say they are at much higher risk of early death or being readmitted.

A team from the University of Warwick say they have identified known risk factors which could indicate those who are at greater risk for once they leave the hospital.

Each risk factor was grouped into one of the following the categories, demographic, socioeconomic, lifestyle, patient medical factors, inpatient stay factors, medication related, laboratory results and glycaemic status.

Professor Theo Arvanitis, from the Institute of Digital Healthcare at WMG, University of Warwick, said: The most common risk factor is in the demographic category of age and the second most important factor is co-morbidity burden; this comes under the patient medical factors category, and means patients have more than one condition.

We also identified BMI as a significant risk within the patient medical factors category, with those who were at the heavier end of the scales to be more at risk.

Thirty-seven of the risk factors we identified from one research paper. This tell us that this research in general is still very early, and more studies are needed to identify the importance and possibly any other risk factors. This could decrease the mortality rate of diabetics discharged from hospitals in the future.

The research paper entitled A Systematic Review Considering Risk factors for Mortality of Patients Discharged from Hospital with a Diagnosis of Diabetes has been published in theJournal of Diabetes and its Complications.

Read more:
People with diabetes discharged from hospital at higher risk of death - Diabetes.co.uk

A team of scientists at Queens University, Belfast, funded by us, have discovered a gene that increases the risk of blood vessel damage in people with diabetes.Switching off this gene could help people with diabetes live longer, healthier lives.

People with diabetes can develop life changing health complications, which can lead to limb amputations, because of blood vessels being damaged due to the disease. Belfast based Professor Andriana Margariti and her team discovered the cells in the damaged blood vessels were dysfunctional in diabetic patients and they then went on to cause cardiovascular conditions such as heart disease.

The three-year 264,000 research study, funded by us, discovered that blood vessel cells were dysfunctional because there was a high level of a protein gene, called QKI-7.

Margariti explained: We found that the level of this gene is very high in people with cardiovascular disease caused by diabetes. We discovered from blood vessels taken from the heart and amputated limbs of diabetic patients that the level of this protein gene is high.

So we learned that the QKI-7 protein gene was a key factor in the malfunction of the blood vessels cells that, in turn, cause cardiovascular complications in people with diabetes.

Of the around 74,000 people in Northern Ireland that have coronary heart disease, around a quarter (around 19,000) will also have diabetes.

Coronary heart disease is the leading cause of premature death in Northern Ireland and the single biggest killer worldwide, while adults with diabetes are up to three times more likely to develop heart and circulatory conditions.

Professor Margariti added: Identifying this gene has the potential to stop the damage to the blood vessels that causes the cardiovascular diseases and amputations.

It is a very important discovery. This will make a difference in the medical and scientific field.

The team also discovered that knocking down (removing) protein gene QKI-7 in diabetic mice resulted in restored blood vessel function.

The blood vessels were able to regenerate and therefore stopping damaging cardiovascular complications from happening. This also provided more evidence on how significant, protein gene QKI-7 is.

Having discovered the gene that causes the malfunction in blood vessels the next step will be to develop a drug that will target QKI-7 to stop the heart and circulatory damage caused by diabetes from developing.

Prof Margariti explained: This BHF funded study will allow the opportunity to propose novel medications to prevent the devastation of diabetic complications such as cardiovascular disease and it will significantly improve the quality of life in diabetic patients.

The results will potentially help treat the cardiovascular complications of diabetes and screen patients earlier, which can be lifesaving and life changing for those people living with diabetes.

Our Head of BHF NI Fearghal McKinney said: The results of this study from Prof Dr Margariti and her team show just how important funding research is. It delivers tangible results that have the potential to save and improve the lives of people living with diabetes.

Unfortunately, coronavirus has a long-lasting and devastating impact on charities like ours, with the BHFs funding for new research falling by a shocking 50m this year alone. That's why, not only do we need urgent help from our loyal supporters, were also urging the UK Government to ensure funding for vital research charities like ours.

For us, it will mean we can protect the progress that world class researchers like Prof Margariti are making and continue to transform the lives of those with heart and circulatory diseases. Its ultimately patients who will suffer if this doesnt happen.

These results were published today in the journal Nature Communications.

Our research in Northern Ireland

Read the rest here:
Gene discovery with potential to prevent complications for diabetes - British Heart Foundation

If youre a diabetic, people might have told you to avoid fruits because they are too sweet or contain sugar that can make your blood glucose go up. But this is a myth that you should stop believing right now. All fruits contain natural sugar (some more than others), but they also contain a good amount of other essential nutrients like vitamins, minerals, fiber, and antioxidants. In fact, eating fruits and vegetables is known to help reduce the risk of developing many health conditions including high blood pressure, heart diseases, strokes, obesity, and certain cancers. People with diabetes are more likely to be affected by these conditions. Therefore, its even more important for diabetes patients to eat more fruits and vegetables. Also Read - Diabetes diet: 6 spices that you should eat to manage your blood sugar levels

Most fruits have a low to medium glycaemic index, a number that tells about how slowly or how quickly a food raises blood glucose levels, compared to other carbohydrate-containing foods like white or wholemeal bread. Also Read - Heres what a typical Ayurvedic diet chart for diabetics looks like

However, portion size is very important when considering fruits as part of your diabetes diet. Because certain fruit choices may affect blood sugar levels more than others, its important to keep an eye on portion sizes. Also Read - Why Ayurveda experts are encouraging diabetics to eat black rice?

One serving of fruit should contain 15 grams of carbohydrates. The size of the serving will depend on the carbohydrate content of the fruit. For example, you can consume a larger portion of a low-carbohydrate fruit, and make it small if its a high-carbohydrate fruit. You can eat all fruits as long as the serving size is limited to 15 grams of carbohydrates. Heres what one serving for common whole fruits should be like:

1/2 medium banana

3/4 cup blueberries

1 cup raspberries or blackberries

1 1/4 cup whole strawberries

1 cup cubed cantaloupe or honeydew melon

1 small piece (4 ounces) apple, orange, peach, pear, or plum

2 small or 1 large tangerine (4 ounces total)

2 small (2 ounces each) kiwi

4 small (1 ounce each) apricots

~1 cup of melon (cantaloupe, watermelon, or honeydew)

17 small grapes or cherries

1/3 medium mango

Fruit juices contain less fiber than the whole fruits and are high in natural sugars. Therefore, its advisable to avoid juices when you have diabetes and instead eat the actual fruit. If you still want to drink fruit juice, have a maximum of a small glass per day. Drinking too much fruit juice may raise your blood glucose levels and make you gain weight.

While dried fruits even higher concentrations of vitamins and minerals, the sugar content also becomes more concentrated. For example, one cup of grapes contains 27 grams of carbs whereas one cup of raisins contains 115 grams of carbs. This means raisins contain more than three times as many carbs as grapes do.

So, avoiding dried fruit and juice may help you better control your blood sugar. The best way to include fresh fruit to your diabetes diet is to pair it with a protein and/or fat. You can top cottage cheese with pineapple, add berries to a protein smoothie, or dip apple slices into nut butter or tahini.

Published : September 14, 2020 3:01 pm | Updated:September 15, 2020 9:02 am

More here:
Should you have fruits if you have diabetes? - TheHealthSite

Losing weight is key to preventing or reversing type 2 diabetes, according to a major study involving nearly half a million people.

The University of Cambridge trial has shown the condition, commonly associated with poor lifestyle, could be avoided if more people kept their weight in a healthy range or below that target.

Lead researcher Professor Brian Ference said their findings of the study could have significant implications for screening, preventing and treating type 2 diabetes.

The trial involved dividing up the 445,765 participants into five groups relating to their genetic risk of diabetes and five groups according to their body mass index (BMI).

The research team discovered the group of those with the highest BMI had an 11-fold increased risk of diabetes compared to the lowest BMI group.

Professor Ference, who unveiled the research results at the annual European Society of Cardiology (ESC) Congress, said: The findings indicate that BMI is a much more powerful risk factor for diabetes that genetic predisposition.

This suggests that when people cross a certain BMI threshold, their chances of diabetes go up and stay at that same high-risk level regardless of how long they are overweight. You can prevent most cases of diabetes by keeping BMI below a persons threshold.

What the results have also shown is that everyone has a different BMI threshold depending on their height and build. This explains why some people who are a healthy weight develop the condition and some who are overweight do not.

Professor Ference added: You can prevent most cases of diabetes by keeping BMI below a persons threshold.

But it (the study) also implies something that we havent focused on in the past and that is we can also probably reverse most cases of diabetes if we lower somebodys BMI aggressively below their BMI threshold relatively soon after they develop diabetes.

I think the fact that BMI appears to have a threshold rather than a cumulative effect on the risk of diabetes really has potentially significant implications for how we think about changing screening, preventing, treating and reversing diabetes.

The multi-award-winning Low Carb Program is demonstrated to help patients with type 2 diabetes, prediabetes and obesity sustainably lose weight, improve blood glucose control and reduce diabetes medications. At 1 year, peer-reviewed research shows 26% of participants who completed the program were in remission.

Read more:
Weight loss is key to type 2 diabetes prevention and reversal - Diabetes.co.uk

"I really would like to stay with Dallas ISD," the third-grade teacher said. "I wish they were practicing more flexibility with teachers."

Jacqueline Martinez has spent the last nine years teaching in Dallas ISD but said Thursday she doesn't know if she will stay beyond next week.

"I will resign. I am not going to go back to campus, Martinez said.

The third-grade teacher is holding class from home right now as the district remains online through Oct. 5.

But, the school district requires teachers who have not already reported to campus to do so by Sept. 17.

Martinez says she has diabetes, making her high risk for complications if she got COVID-19.

Dallas ISD offered an option to teachers last month through an Alternative Work Arrangement, or AWA waiver, which allows employees to work remotely if they can complete 100% of their work.

Right now, Dallas teachers can do that but as the district plans to welcome students back to campus, some as early as Sept. 28, doing all the teaching work remotely will not be possible.

"I applied for the AWA and was denied," Martinez said. "I don't know anyone that's been approved."

On Thursday, the district's HR department, Human Capital Management, told school board trustees the majority of teachers who applied for the waiver did so because of a lack of available child care.

Cynthia Wilson, the head of the department, said the district changed its policy to allow teachers to bring their children to school while they teach remotely.

Wilson said teachers with underlying health conditions who were denied the district's waiver can seek alternatives, including a waiver as part of the Americans with Disabilities Act.

District 7 trustee Ben Mackey said the process for who is eligible to receive an alternative work arrangement needs to be clearer.

"The clarity would go a long way about what qualifies and what doesnt, Mackey said.

Diedrae Bell-Hunter with Human Capital Management says the district held virtual town halls about options for teachers but said it's likely the message wasn't entirely received.

It is a little bit complicated but we do have other options outside the AWA process," Bell-Hunter said. "We still have leaves available to employees that will protect those who have underlying medical conditions.

Martinez said late Thursday she is talking with the district's benefits department about her situation, but if it is not resolved in the next week, she won't have a choice but to resign from her position.

"I really would like to stay with Dallas ISD," she said. "I wish they were practicing more flexibility with teachers."

Here is the original post:
Dallas teacher with diabetes says she may resign after denied waiver to work from home - WFAA.com

Despite recommendations to the contrary, screening rates for diabetic retinopathy among pediatric patients with type 1 and 2 diabetes remain low. Point-of-care screening is available for diabetic retinopathy screening, but its cost-effectiveness compared with standard screening by an eye care professional (ECP) is unclear. According to a recent study, the use of artificial intelligence (AI) in diabetic retinopathy screening among pediatric patients with type 1 and 2 diabetes was effective and resulted in cost savings.

Data collection spanning 1994 through 2019 included out-of-pocket costs for autonomous AI screening, ophthalmology visits, and treating diabetic retinopathy; probability of standard retinal examination receipt; relative screening odds; and the sensitivity, specificity, and diagnosability of the ECP versus autonomous AI screenings. The main outcomes were patient costs or savings, per mean patient payment for diabetic retinopathy screening examination, as well as cost-effectiveness, per costs or savings correlated with the number of true-positive results that diabetic retinopathy screening yielded.

In standard ophthalmologic screening performed by an ECP, the expected true-positive proportions for type 1 and 2 diabetes were 0.006 and 0.01, respectively; for autonomous AI, they were 0.03 and 0.04, respectively. With a base case scenario of 20% adherence, autonomous AI use resulted in a higher mean payment than conventional ECP screening for both patients with type 1 ($8.52 vs. $7.91) and type 2 ($10.85 vs. $8.20) diabetes. But with an adherence rate of at least 23%, autonomous AI was the preferred screening strategy.

These results suggest that point-of-care diabetic retinopathy screening using autonomous AI systems is effective and cost saving for children with diabetes and their caregivers at recommended adherence rates, the study authors summarized.

View original post here:
Effectiveness, Cost Savings of AI to Screen for Pediatric Diabetic Retinopathy - DocWire News

A LIFE-CHANGING new diet shown to put type 2 diabetes into remission has given hope to millions of people.

The Diabetes Remission Clinical Trial, or DiRECT, has been carried out in Scotland with a high success rate and Professor Michael Lean, who heads the treatment, believes this proves the disease can be treated.

9

And earlier this month it emerged that thousands of people will now be prescribed the life-changing programme on the NHS.

Prof Lean says: The treatment starts by putting patients on to a weight-loss plan of shakes and soups, 850 calories a day for 12 weeks.

The weight loss reduces the level of fat inside the liver and pancreas, which is what puts the diabetes into remission.

The critical next phase is to guide patients towards a new normal eating plan of different foods from when they had diabetes.

9

With type 2 diabetes costing the NHS 10billion every year, Prof Leans treatment could save vital funds, but more importantly, lives, so it is to be rolled out to around 5,000 patients in ten areas of the UK.

People who have been diagnosed with type 2 diabetes in the last six years will be considered for the diet.

Patients will still have to meet certain criteria before their GP can refer them.

Under the year-long plan, patients will be given shakes and soups for three months, as well as support to increase their exercise levels.

They will also be given plans to re-introduce solid food, as well as support and virtual sessions with coaches and dietitians over the remaining months.

The diet is currently available across NHS trusts in South Yorkshire and Bassetlaw, Humber Coast and Vale, Greater Manchester, Frimley,

Gloucestershire, Derbyshire, Birmingham and Solihull, Bedfordshire, Luton and Milton Keynes (BLMK), North East London and North Central London.

Nearly four million people in the UK are living with a form of diabetes and it is estimated that 90 per cent of them have type 2.

Type 2 diabetes is an incredibly serious condition but unlike cancer its entirely reversible

Unlike type 1 diabetes, which is a serious, often life-long condition, it is widely accepted that type 2 diabetes is linked to lifestyle factors.

Being overweight, getting older and having high blood pressure all increase a persons risk of developing the condition.

And despite the fact that it can cause strokes and heart disease, increasing the risk of heart attacks, still too many people are oblivious to the risk.

Prof Lean, from Glasgow University, tells The Sun: Theres misinformation that diabetes isnt too serious a condition to have, and you can live well with it by taking medication.

9

That couldnt be further from the truth. The fact is that ten-year survival rates for breast cancer are better than they are for type 2 diabetes.

Youre more likely to die younger, and with more pain and disabilities from type 2 than you are from breast cancer.

Its an incredibly serious condition but unlike cancer its entirely reversible.

So what is it like to live on a restrictive diet that cuts your calorie count to just 800 a day?

Here, three volunteers from Prof Leans studies share their journey into type 2 diabetes remission having lost 12st between them.

IN just seven months, Edward McGeachie has reversed his type 2 diabetes and lost five stone thanks to the trial.

The company director from Glasgow was diagnosed in January but he thinks he had it years before.

9

A routine health check found he weighed 20 stone and that he had through the roof blood pressure and high blood sugar levels.

He emailed Prof Lean asking to take part in the trial after seeing it on the news and says the diet was the easiest thing Ive ever done.

Edward, 54, says: I was in a critical condition when I started.

"I was probably a few years away from a massive heart attack and morbidly obese I had nowhere to go.

"I was in the danger zone and it was all the motivation I needed.

He was so dedicated to the trial that when he went on holiday to Malaga in February he took his blender with him.

Edward says: Within a few months I was told Id extended my life expectancy by ten years.

"Knowing Ive made such huge changes to my health has been incredible. It has been life-changing in every way.

9

Edward put solid food back into his diet in June and is like a new man.

Im healthier, fitter, I go to the gym, Ive got more energy, Ive stopped snoring which pleased my wife and all the health and weight related issues are gone.

Ive learned so much about food, I wont ever eat in the same way again.

YEARS of travelling with work and having little time to exercise meant Eddie Morrisons weight crept up and up, reaching 18 stone.

In December 2010 at the age of 55, a routine medical at work showed he was suffering type 2 diabetes, and he started on medication.

9

After five years on drugs, it was the birth of his granddaughter Lucy that was the final straw for Eddie.

While his condition wasnt debilitating, he could see a future plagued with serious health concerns.

When his GP told him about the DiRECT trial in August 2015, he realised it was too good an opportunity to miss.

The retired fuels logistics manager says: A few months into the treatment, Id already lost two stone it was the incentive I needed to carry on.

9

Now 13st 2lb, Eddie, from Glasgow, weighs the same as he did in his 20s. He is medication-free and his type 2 diabetes is in remission.

He says: The dietitians taught me about weighing food and what a balanced plate looks like. And by January 2016, I was down to 13st 6lb and needed a whole new wardrobe.

Eddie is still on the trial now, and his weight has stayed even despite the odd blow out to celebrate beers with friends after a game of golf, or birthday cake with his granddaughter.

He says: I never thought when I had the diagnosis, after years on medication, Id be in remission, medication-free and walking up to 100 miles a week but Im fitter and healthier than ever and its all because my GP gave me the chance to take part in a trial that changed my life.

Different types of diagnosis

DIABETES is a serious condition where a persons blood sugar level is too high.

Type 1 diabetes is where the bodys immune system attacks and destroys the cells in the pancreas that produce insulin, meaning the body can no longer make the hormone.

But type 2 is a bit different it can be prevented and treated.

If you have type 2 it means your body cant make enough insulin, or that insulin cant work properly.

But why is insulin so important?We all need some glucose (sugar) in our blood, and we get that from food it gives us energy.

Once its broken down, it is released into the bloodstream.

From there insulin acts like a key, unlocking the door to our cells and letting the glucose in to fuel our bodies.

But if that insulin doesnt work, and the key doesnt fit, the glucose has nowhere to go and builds up in the blood, causing a spike in sugar levels.

Over a long period of time, left untreated, this can cause serious damage to your heart, eyes, kidneys and other organs causing heart disease among other complications.

A ROUTINE blood test led to Beverly Iceton being diagnosed with type 2 diabetes in October 2018.

But within months, she said the drugs she was taking for it stopped her sleeping and she constantly felt sick.

9

Bev, 57, was desperate for a place when she came across the trial online in February 2019.

Most likely I had had it for a few years by the time I was diagnosed, says the admin assistant.

I tried different medications but my quality of life wasnt great and the side effects were getting tougher to deal with.

Other trials had morbidly obese participants but this one wanted to replicate the results in people with a BMI below 27 overweight is 25 to 29.9 who had diabetes for less than six years.

9

Bev, from Barnard Castle, Co Durham, says: Living on 850 calories a day in shakes and soups for eight weeks sounds restrictive, and when you tell people, they say they could not do it but its about far more than just shakes.

The support, the re-education, the accountability it changes the way you see food.

Within eight weeks of starting the trial, I was down from 12st 5lb to 10st 5lb, my bloods showed I was in remission and Ive stayed that way ever since.

I look at food so differently now but I can treat myself or have a blow out.

TINY BUT DEADLYI lost my dad to skin cancer then this tiny mole turned out to be melanoma

LIFE SAVERShowing GP photo of my girl saved her life after spotting tell-tale cancer sign

DR GOOGLE From thrush to warts the 10 symptoms Brits are too embarrassed to talk about

ON CALL1million Brits have undiagnosed type 2 diabetes - the warning signs to look out for

TELLING SIGNMy baby girls dark wee was the first clue she had an incurable disease

"Its just on occasion once every couple of months.

"I didnt think it was possible to reverse diabetes, let alone in such a short space of time.

"I cant thank the team enough.

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAILexclusive@the-sun.co.uk

Read the original here:
We reversed our type 2 diabetes and lost 12st between us on life-changing new shake diet - The Sun

Nanomedicine Market Overview:

Reports and Data has recently published a new research study titled Global Nanomedicine Market that offers accurate insights for the Nanomedicine market formulated with extensive research. The report explores the shifting focus observed in the market to offer the readers data and enable them to capitalize on market development. The report explores the essential industry data and generates a comprehensive document covering key geographies, technology developments, product types, applications, business verticals, sales network and distribution channels, and other key segments.

The report is further furnished with the latest market changes and trends owing to the global COVID-19 crisis. The report explores the impact of the crisis on the market and offers a comprehensive overview of the segments and sub-segments affected by the crisis. The study covers the present and future impact of the pandemic on the overall growth of the industry.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1048

Competitive Landscape:

The global Nanomedicine market is consolidated owing to the existence of domestic and international manufacturers and vendors in the market. The prominent players of the key geographies are undertaking several business initiatives to gain a robust footing in the industry. These strategies include mergers and acquisitions, product launches, joint ventures, collaborations, partnerships, agreements, and government deals. These strategies assist them in carrying out product developments and technological advancements.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation, and Johnson & Johnson.

An extensive analysis of the market dynamics, including a study of drivers, constraints, opportunities, risks, limitations, and threats have been studied in the report. The report offers region-centric data and analysis of the micro and macro-economic factors affecting the growth of the overall Nanomedicine market. The report offers a comprehensive assessment of the growth prospects, market trends, revenue generation, product launches, and other strategic business initiatives to assist the readers in formulating smart investment and business strategies.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/nanomedicine-market

Product Outlook (Revenue, USD Billion; 2017-2027)

Drug Delivery System Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048

Key Coverage in the Nanomedicine Market Report:

Thank you for reading our report. Please get in touch with us if you have any queries regarding the report or its customization. Our team will make sure the report is tailored to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Hydroxycitronellal Market: Hydroxycitronellal Market To Reach USD 192.7 Million By 2027

Sterile Filtration Market: Sterile Filtration Market To Reach USD 8.48 Billion By 2027 | CAGR: 7.7%

Tissue Diagnostics Market: Tissue Diagnostics Market To Reach USD 5.02 Billion By 2027

UV-C Robot Market: UV-C Robot Market to Reach USD 1.46 Billion by 2027

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

Read this article:
Nanomedicine Market Provides in-depth analysis of the Nanomedicine Industry, with current trends and future estimations to elucidate the investment...

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 (the "Registration Statement"), which includes a preliminary proxy statement/consent solicitation statement/prospectus, in connection with its recently-announced proposed business combination with Clene Nanomedicine, Inc. ("Clene"), a clinical-stage biopharmaceutical company developing a potential therapeutic nanocatalyst for the treatment of neurodegenerative diseases in addition to a nanotechnology based-therapy with antiviral applications.

Tottenham's ordinary shares are currently traded on Nasdaq under the symbol "TOTA". In connection with the closing of the transaction, Tottenham intends to change its name to Clene Inc., reincorporate in Delaware (by merging with Chelsea Worldwide Inc.) and remain Nasdaq-listed under a new ticker symbol. Completion of the transaction is subject to approval by Tottenham shareholders, Clene's stockholders, the Registration Statement being declared effective by the SEC, a concurrent closing of private placements and other customary closing conditions.

Chardan is acting as the M&A advisor to Tottenham. LifeSci Capital LLC is acting as the M&A advisor to Clene. Loeb & Loeb LLP is acting as legal advisor to Tottenham. Kirkland & Ellis LLP along with Stoel Rives LLP, Clene's local counsel, are acting as legal advisors to Clene.

About Clene Nanomedicine, Inc.

Clene Nanomedicine, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the development of unique therapeutic candidates for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based inSalt Lake City, Utahwith R&D and manufacturing operations located inNorth East, Maryland. For more information, please visitwww.clene.com.

About Tottenham Acquisition I Limited

Tottenham Acquisition I Limited is a blank check company formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities. Tottenham's efforts to identify a prospective target business were not limited to a particular industry or geographic region, although the company initially focused on operating businesses in the TMT (Technology, Media, Telecom), education, e-commerce, health-care and consumer goods industries with primary operations inAsia(with an emphasis inChina).

Forward-Looking Statements

This press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties identified in the Form S-4 filed by Chelsea Worldwide relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission ("SEC") made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Important Information

Chelsea Worldwide Inc., Tottenham, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of Tottenham ordinary shares in respect of the proposed transaction described herein. Information about Tottenham's directors and executive officers and their ownership of Tottenham's ordinary shares is set forth in Tottenham's Annual Report on Form 10-K filed with the SEC, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation are included in the Form S-4 pertaining to the proposed transaction. These documents can be obtained free of charge from the sources indicated below.

In connection with the transaction described herein, Chelsea Worldwide Inc. will file relevant materials with the SEC including a Registration Statement on Form S-4. Promptly after the Registration Statement is declared effective, Tottenham will mail the proxy statement and a proxy card to each shareholder entitled to vote at the extraordinary general meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS OF TOTTENHAM ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT TOTTENHAM WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TOTTENHAM, CLENE AND THE TRANSACTION. The proxy statement/consent solicitation/prospectus and other relevant materials in connection with the transaction (when they become available), and any other documents filed by Tottenham with the SEC, may be obtained free of charge at the SEC's website (www.sec.gov).

SOURCE Tottenham Acquisition I Limited

See the article here:
Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with...

The world-altering coronavirus behind the COVID-19 pandemic is thought to be just 60 nanometres to 120 nanometres in size. This is so mind-bogglingly small that you could fit more than 400 of these virus particles into the width of a single hair on your head. In fact, coronaviruses are so small that we cant see them with normal microscopes and require much fancier electron microscopes to study them. How can we battle a foe so minuscule that we cannot see it?

One solution is to fight tiny with tiny. Nanotechnology relates to any technology that is or contains components that are between 1nm and 100nm in size. Nanomedicine that takes advantage of such tiny technology is used in everything from plasters that contain anti-bacterial nanoparticles of silver to complex diagnostic machines.

Nanotechnology also has an impressive record against viruses and has been used since the late 1880s to separate and identify them. More recently, nanomedicine has been used to develop treatments for flu, Zika, and HIV. And now its joining the fight against the COVID-19 virus, SARS-CoV-2.

If youre suspected of having COVID, swabs from your throat or nose will be taken and tested by reverse transcription polymerase chain reaction (RT-PCR). This method checks if genetic material from the coronavirus is present in the sample.

Despite being highly accurate, the test can take up to three days to produce results, requires high-tech equipment only accessible in a lab, and can only tell if you have an active infection when the test is taken. But antibody tests, which check for the presence of coronavirus antibodies in your blood, can produce results immediately, wherever youre tested.

Antibodies are formed when your body fights back against a virus. They are tiny proteins that search for and destroy invaders by hunting for the chemical markers of germs, called antigens. This means antibody tests can not only tell if you have coronavirus but if you have previously had it.

[Read: Oxfords COVID-19 vaccine is starting to look like a winner]

Antibody tests use nanoparticles of materials such as gold to capture any antibodies from a blood sample. These then slowly travel along with a small piece of paper and stick to an antigen test line that only the coronavirus antibody will bond to. This makes the line visible and indicates that antibodies are present in the sample. These tests are more than 95% accurate and can give results within 15 minutes.

A major turning point in the battle against coronavirus will be the development of a successful vaccine. Vaccines often contain an inactive form of a virus that acts as an antigen to train your immune system and enable it to develop antibodies. That way, when it meets the real virus, your immune system is ready and able to resist infection.

But there are some limitations in that typical vaccine material can prematurely break down in the bloodstream and does not always reach the target location, reducing the efficiency of a vaccine. One solution is to enclose the vaccine material inside a nanoshell by a process called encapsulation.

These shells are made from fats called lipids and can be as thin as 5nm in diameter, which is 50,000 times thinner than an eggshell. The nanoshells protect the inner vaccine from breaking down and can also be decorated with molecules that target specific cells to make them more effective at delivering their cargo.

This can improve the immune response of elderly people to the vaccine. And critically, people typically need lower doses of these encapsulated vaccines to develop immunity, meaning you can more quickly produce enough to vaccinate an entire population.

Encapsulation can also improve viral treatments. A major contribution to the deaths of virus patients in intensive care is acute respiratory distress syndrome, which occurs when the immune system produces an excessive response. Encapsulated vaccines can target specific areas of the body to deliver immunosuppressive drugs directly to targeted organs and helping regulate our immune system response.

Its hard to exaggerate the importance of wearing face masks and washing your hands to reducing the spread of COVID-19. But typical face coverings can have trouble stopping the most penetrating particles of respiratory droplets, and many can only be used once.

New fabrics made from nanofibres 100nm thick and coated in titanium oxide can catch droplets smaller than 1,000nm and so they can be destroyed by ultraviolet (UV) radiation from sunlight. Masks, gloves, and other personal protective equipment (PPE) made from such fabrics can also be washed and reused, and are more breathable.

New fabrics made from coated nanofibres could produce better PPE. AnnaVel/Shutterstock

Another important nanomaterial is graphene, which is formed from a single honeycomb layer of carbon atoms and is 200 times stronger than steel but lighter than paper. Fabrics laced with graphene can capture viruses and block them from passing through. PPE containing graphene could be more puncture, flame, UV, and microbe-resistant while also being lightweight.

Graphene isnt reserved for fabrics either. Nanoparticles could be placed on surfaces in public places that might be particularly likely to facilitate the transmission of the virus.

These technologies are just some of the ways nanoscience is contributing to the battle against COVID-19. While there is no one answer to a global pandemic, these tiny technologies certainly have the potential to be an important part of the solution.

This article is republished from The Conversation by Josh Davies, PhD Candidate in Chemistry, Cardiff University under a Creative Commons license. Read the original article.

Read next: Schools are buying up surveillance technology to fight COVID-19

Read the original here:
How very tiny technologies are helping tackle the global pandemic - The Next Web

Highlights

This antibody component, which is 10 times smaller than a full-sized antibody, has been used to construct a drugknown as Ab8for potential use as a therapeutic and prophylactic against SARS-CoV-2.

The researchers report today in the journal Cellthat Ab8 is highly effective in preventing and treating SARS-CoV-2 infection in mice and hamsters.

Its tiny size not only increases its potential for diffusion in tissues to better neutralize the virus, but also makes it possible to administer the drug by alternative routes, including inhalation.

Importantly, it does not bind to human cellsa good sign that it wont have negative side-effects in people.

Ab8 was evaluated in conjunction with scientists from the University of North Carolina at Chapel Hill (UNC) and University of Texas Medical Branch (UTMB) at Galveston, as well as the University of British Columbia and University of Saskatchewan.

Ab8 not only has potential as therapy for the pandemic, but it also could be used to keep people from getting SARS-CoV-2 infections, said co-authorJohn Mellors, chief of the Division of Infectious Diseases at Pitt and UPMC. Antibodies of larger size have worked against other infectious diseases and have been well tolerated, giving us hope that it could be an effective treatment for patients with the disease and for protection of those who have never had the infection and are not immune. Xianglei Liu of Pitt is also co-lead author.

Wei Li, assistant director of Pitts Center for Therapeutic Antibodies and co-lead author of the research, sifted through antibody components and found multiple therapeutic antibody candidates in record time. (UPMC)

The tiny antibody component is the variable, heavy chain (VH) domain of an immunoglobulin, which is a type of antibody found in the blood. It was found by fishing in a pool of more than 100 billion potential candidates using the SARS-CoV-2 spike protein as bait.

Ab8 is created when the VH domain is fused to part of the immunoglobulin tail region, adding the immune functions of a full-size antibody without the bulk.

Like the Pitt and UPMC vaccine candidatePittCoVaccthat delivers an immunization through a spiky Band-Aid-like patch and overcomes the need for needles and refrigeration, the researchers are thinking outside the box when it comes to how Ab8 could be administered.

Its small size might allow it to be given as an inhaled drug or intradermally, rather than intravenously through an IV drip, like most monoclonal antibodies currently in development.

Abound Bio, a newly formed UPMC-backed company, has licensed Ab8 for worldwide development.

Dimiter Dimitrov, senior author of the Cell publication and director of PittsCenter for Antibody Therapeutics, was one of the first to discover neutralizing antibodies for the original SARS coronavirus in 2003. In the ensuing years, his team discovered potent antibodies against many other infectious diseases, including those caused by MERS-CoV, dengue, Hendra and Nipah viruses. The antibody against Hendra and Nipah viruses has been evaluated in humans and approved for clinical use on a compassionate basis in Australia.

Clinical trials are testing convalescent plasmawhich contains antibodies from people who already had the pandemicas a treatment for those battling the infection, but there isnt enough plasma for those who might need it, and it isnt proven to work.

Thats why Dimitrov and his team set out to isolate the gene for one or more antibodies that block the SARS-CoV-2 virus, which would allow for mass production.

The pandemic is a global challenge facing humanity, but biomedical science and human ingenuity are likely to overcome it, said Mellors, also Distinguished Professor of Medicine, who holds the Endowed Chair for Global Elimination of HIV and AIDS at Pitt. We hope that the antibodies we have discovered will contribute to that triumph.

This research was funded by National Institutes of Health grants, as well as UPMC; the Burroughs Wellcome Fund; a Canada Excellence Research Chair Award; Genome BC, Canada; Canadian Institutes for Health Research; and Canadian Foundation for Innovation.

To learn more about this research,watch a livestream on Sept. 15 at 2 p.m. ET.

Originally posted here:
AB8 Nano Sized Antibody - the Next Big Thing in Pandemic Prevention & Cure - Drew Reports News

Early development is characterized by the rapid proliferation of embryonic cells, which then differentiate to produce the many specialized types of cells that make up the tissues and organs of multicellular animals. As cells differentiate, their rate of proliferation usually decreases, and many cells in adult animals are arrested in the G0 stage of the cell cycle.

Cell proliferation is carefully balanced with cell death to maintain a constant number of cells in adult tissues and organs. Somatic cells in the adult can be grouped into three general categories with respect to cell proliferation:

Static cell population: These are non-dividing permanent cells, thus they would not be replaced if injured or lost. They leave the cell cycle to perform a specialized function. Static cells include cardiac muscle fibers and neurons.

Stable cell population: These are quiescent cells that do not usually divide. They are considered to be in the G0 phase but be they may be stimulated to divide by appropriate signals as injury, thus their renewal occurs by duplication of existing cells. They include smooth muscle fibers and the epithelial cells of most internal organs such as the liver and kidney.

Labile cell population: These are fully differentiated cells that do not themselves proliferate. instead, their continuous renewal is via the proliferation of the less differentiated stem cells. They include all cells that have a short life span as blood cells, epithelial cells of the skin (skin epidermis), and epithelial cells lining the digestive tract.

It is the process by which unspecialized cells (as embryonic or regenerative cells) acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism.

They are primal cells which are the source, or stem for all of the specialized cells that form organs and tissues.

Stem cell possesses two properties:

They have the potential to generate all types of cells and tissues and can construct a complete, viable organism. Totipotent stem cells are derived from the cells produced by the first few divisions of the fertilized ovum ( morula cells).

They are the descendants of totipotent cells, derived from the inner cell mass of the blastocyst. They can differentiate into more than 220 cell types in the adult body, these are the derivatives of the three primary germ layers, ectoderm, endoderm, and mesoderm. Pluripotent stem cells undergo further specialization into multipotent progenitor cells.

They can produce cells of a closely-related family. They include the multipotent hematopoietic stem cells that can differentiate into red blood cells, white blood cells, and platelets.

They can produce mature cells of a single type but still, have the property of self-renewal which distinguishes them from non-stem cells. They include stem cells in the skin epidermis.

The normal cells are able to handle normal physiologic demands. If the cell is exposed to severe stresses, it goes into cellular adaptations. When the adaptive response to a stimulus is exceeded, reversible or irreversible cell injury occurs. If the stimulus persists, the cell reaches a point of no return and ultimately cell death. There are 2 different mechanisms of cell death, necrosis, and apoptosis.

Necrosis = accidental cell death: it is a pathological process due to various unfavorable factors e.g. hypoxia, radiation, or as a result of pathogens such as viruses.

It is a physiological process controlled by several genes, during which loss of mitochondrial function initiates a cascade of reactions that can set on cell death. Apoptosis occurs in many conditions, including:

Cell division types, Mitosis, Meiosis, Reductional division & Equatorial division

Regulation of the cell cycle, DNA synthesis phase, Interphase & Mitosis

Cytoplasmic organelles, Ribosomes & Endoplasmic reticulum function, structure & definition

Cell Structure, the function of Golgi apparatus, Endosomes & Lysosomes

The function of Cytoplasmic organelles, Mitochondria, Peroxisomes & Cytoskeleton

Structure of Cytoplasm, The function of centrosome & Cytoplasmic inclusions

Nucleus components, function, diagram & classification of chromosomes

Importance of Nucleosides, Nucleotides, Purines, Pyrimidines & Sugars of nucleic acids

More:
Cell proliferation, mechanisms of Cell Death, types ...

The detailed analysis of adenosquamous cancer of the pancreas (ASCP) suggested FGFR and RORC were two promising therapeutic targets.

Using preclinical models, researchers have identified two promising therapeutic targets for the most aggressive and lethal form of pancreatic cancer, adenosquamous cancer of the pancreas (ASCP).

The team of researchers led by Mayo Clinic and the Translational Genomics Research Institute (TGen), both US, suggested fibroblast growth factor receptor (FGFR) and Retinoic acidrelated orphan receptor C (RORC) inhibitors that are already available in clinic could be effective against ASCP.

Dr Daniel Von Hoff, Distinguished Professor and TGens Physician-In-Chief, considered one of the nations foremost authorities on pancreatic cancer and one of the studys authors, said: The rarity of ASCP, the scarcity of tissue samples suitable for high resolution genomic analyses and the lack of validated preclinical models, has limited the study of this particularly deadly subtype of pancreatic cancer.

Where pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and the US third leading cause of cancer-related death (according to the American Cancer Society); ASCP is a rare and particularly aggressive form of pancreatic cancer, diagnosed in less than four percent of patients.

ASCP currently has no effective therapies. Unlike PDAC, ASCP is defined by the presence of more than 30 percent squamous (skin-like) epithelial cells in the tumour. The normal pancreas does not contain squamous cells, said the studys senior author, Dr Michael Barrett, who holds a joint research appointment at Mayo Clinic and TGen.

Dr Barrett explained that in their study they discovered ASCPs have novel mutations and deletions in genes that regulate tissue development and growth, alongside those typically evident in PDAC. As a consequence, cells within the tumour have the ability to revert to a stem-cell-like state that includes changes in cell types and appearance, and the activation of signalling pathways that drive the aggressive nature of ASCP.

He added that while the aggressive stem-like state is very resistant to current pancreatic cancer therapies, the study indicated ASCP could be targeted by drugs currently in clinical use.

Using multiple analysis methods, the research team conducted what is believed to be the most in-depth analysis of ASCP tissue samples.

They identified multiple mutations and genomic variants that are common to both PDAC and ASCP, but highlighted two significant therapeutic targets that were unique to ASCP genomes alone: FGFR signalling, inhibition of FGFR signalling had a significant effect on organoids harbouring the FGFR1-ERLIN2 gene fusion; and a pancreatic cancer stem cell regulator known as RORC.

The team concluded in their study: Of significant interest will be clinical trials with FGFR and RORC inhibitors that include correlative studies of genomic and epigenomic lesions in both ASCP and PDAC.

The paper was published in Cancer Research.

Here is the original post:
Study identifies therapeutic targets for most lethal pancreatic cancer - Drug Target Review

Global Cancer Stem Cells Market Insights by Application, Product Type, Competitive Landscape & Regional Forecast 2025 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and development, drivers, capacities, technologies, and on the changinginvestment structure of the Global Cancer Stem Cells Market. Some of the key players profiled in the study are Thermo Fisher Scientific, Inc. (United States), AbbVie, Inc.(United States), The Merck KGaA Group (Germany), Bionomics (Australia), Lonza Group (Switzerland), Stemline Therapeutics, Inc.(United States), Fujifilm Irvine Scientific (United States), STEMCELL Technologies Inc. (Canada), Sino Biological Inc. (United States) and BIOTIME, Inc. (United States).

You can get free access to samples from the report here:https://www.htfmarketreport.com/sample-report/2134979-global-cancer-stem-cells-market-2

Market Snapshot:According to the World Health Organization, Cancer is the second leading cause of death globally, and is responsible for an estimated 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer. Hence, there is a need for a tremendous research on Cancer Cells. Cancer stem cells (CSCs) refers to the cells which are obtained from tumor that posses potential to reproduce all types of cancer cells found in a cancer sample.These cells are grown in tumors as a separate population and thereby it causes Deterioration and Metastasis of Existing tumor through generation of new tumor. Hence, with the Advancement in Technology Especially in Cancer Stem Cells Research area, Therapies specific to Targeting Cancer Stem Cells are anticipated to drive the Global Cancer Stem Cells Market.

Market DriversIncreasing Prevalence of Cancer leading to rapidly rising burden of the mortality rate of Cancer among PatientsThe Continuous Rise in the number of Research Studies and Development on Cancer Stem Cells (CSCs)The Government initiatives to boost the Cancer Research activities and availability of funds.

Market TrendImprovements in experimental approaches by the Researchers such as, In vitro assay has enabled them to establish a relationship between different cell types in a tumor and their microenvironmentThis has led to the Development of a Broad Therapeutic Portfolio for CSCs and their associated key pathways.

RestraintsHigh Costs related to Cancer Stem Cell Therapeutics may hamper market growth.

Cancer Stem Cells Market: Demand Analysis & Opportunity Outlook 2025

Cancer Stem Cells research study is to define market sizes of various segments & countries by past years and to forecast the values by next 5 years. The report is assembled to comprise each qualitative and quantitative elements of the industry facts including: market share, market size (value and volume 2014-19, and forecast to 2025) which admire each countries concerned in the competitive examination. Further, the study additionally caters the in-depth statistics about the crucial elements which includes drivers & restraining factors that defines future growth outlook of the market.

Important years considered in the study are:Historical year 2014-2019 ; Base year 2019; Forecast period** 2020 to 2025 [** unless otherwise stated]

Enquire for customization in Report @https://www.htfmarketreport.com/enquiry-before-buy/2134979-global-cancer-stem-cells-market-2

The segments and sub-section of Cancer Stem Cells market are shown below:

The Study is segmented by following Product Type: Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis and Others

Major applications/end-users industry are as follows: Breast Cancer Diagnosis and Treatment , Prostate Cancer Diagnosis and Treatment , Colorectal Cancer Diagnosis and Treatment , Lung Cancer Diagnosis and Treatment and Other Cancers Diagnosis and Treatment

Some of the key players/Manufacturers involved in the Market are Thermo Fisher Scientific, Inc. (United States), AbbVie, Inc.(United States), The Merck KGaA Group (Germany), Bionomics (Australia), Lonza Group (Switzerland), Stemline Therapeutics, Inc.(United States), Fujifilm Irvine Scientific (United States), STEMCELL Technologies Inc. (Canada), Sino Biological Inc. (United States) and BIOTIME, Inc. (United States)

If opting for the Global version of Cancer Stem Cells Market analysis is provided for major regions as follows: North America (USA, Canada and Mexico) Europe (Germany, France, the United Kingdom, Netherlands, Russia , Italy and Rest of Europe) Asia-Pacific (China, Japan, Australia, New Zealand, South Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia, rest of countries etc.) Middle East and Africa (Saudi Arabia, United Arab Emirates, Israel, Egypt, Nigeria and South Africa)

Buy this research report @https://www.htfmarketreport.com/buy-now?format=1&report=2134979

Key Answers Captured in Study areWhich geography would have better demand for product/services?What strategies of big players help them acquire share in regional market?Countries that may see the steep rise in CAGR & year-on-year (Y-O-Y) growth?How feasible is market for long term investment?What opportunity the country would offer for existing and new players in the Cancer Stem Cells market?Risk side analysis involved with suppliers in specific geography?What influencing factors driving the demand of Cancer Stem Cells near future?What is the impact analysis of various factors in the Global Cancer Stem Cells market growth?What are the recent trends in the regional market and how successful they are?

Read Detailed Index of full Research Study at @https://www.htfmarketreport.com/reports/2134979-global-cancer-stem-cells-market-2

There are 15 Chapters to display the Global Cancer Stem Cells market.Chapter 1, About Executive Summary to describe Definition, Specifications and Classification of Global Cancer Stem Cells market, Applications [Breast Cancer Diagnosis and Treatment , Prostate Cancer Diagnosis and Treatment , Colorectal Cancer Diagnosis and Treatment , Lung Cancer Diagnosis and Treatment and Other Cancers Diagnosis and Treatment], Market Segment by Types Cell Culturing, Cell Separation, Cell Analysis, Molecular Analysis and Others;Chapter 2, objective of the study.Chapter 3, to display Research methodology and techniques.Chapter 4 and 5, to show the Cancer Stem Cells Market Analysis, segmentation analysis, characteristics;Chapter 6 and 7, to show Five forces (bargaining Power of buyers/suppliers), Threats to new entrants and market condition;Chapter 8 and 9, to show analysis by regional segmentation[North America, Europe, Asia-Pacific etc ], comparison, leading countries and opportunities; Regional Marketing Type Analysis, Supply Chain AnalysisChapter 10, to identify major decision framework accumulated through Industry experts and strategic decision makers;Chapter 11 and 12, Global Cancer Stem Cells Market Trend Analysis, Drivers, Challenges by consumer behavior, Marketing ChannelsChapter 13 and 14, about vendor landscape (classification and Market Ranking)Chapter 15, deals with Global Cancer Stem Cells Market sales channel, distributors, Research Findings and Conclusion, appendix and data source.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia or Oceania [Australia and New Zealand].

About Author:HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the Accurate Forecast in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their Goals & Objectives.

Contact US :Craig Francis (PR & Marketing Manager)HTF Market Intelligence Consulting Private LimitedUnit No. 429, Parsonage Road Edison, NJNew Jersey USA 08837Phone: +1 (206) 317 1218[emailprotected]

Connect with us atLinkedIn|Facebook|Twitter

Go here to see the original:
Cancer Stem Cells Market to witness astonishing growth by 2026 | AbbVie, The Merck KGaA Group, Bionomics, Lonza Group - The PRNews Pulse

KIRKLAND, QC, Sept. 15, 2020 /CNW/ - Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that Health Canada has approved BRENZYS, a TNF-inhibitor, for four new indications:

BRENZYS is a type of protein called a tumour necrosis factor (TNF) blocker that blocks the action of a substance the body makes called TNF-alpha. TNF-alpha is made by the body's immune system.5 People with immune diseases like JIA, PsA and PsO have too much TNF-alpha in their bodies, which can cause inflammation and lead to painful, swollen joints and raise thick, red, scaly patches ("psoriatic skin lesions") that can appear anywhere on the body.6 It can reduce the amount of TNF in the body to normal levels, helping to treat joint damage and psoriatic skin conditions. 7

An estimated one million Canadians live with psoriasis,8 and between 10 and 30% of these patients will develop psoriatic arthritis.9 Plaque Psoriasis is an inflammatory disease that affects the skin and can cause psoriatic skin lesions that can appear anywhere on the body.10 About 80% to 90% of people with psoriasis have plaque psoriasis, the most common type of psoriasis.11 PsA is usually seen in patients with PsO and affects both the joints and the skin.12 JIA is an inflammatory disease that affects the joints in the body and is the most common type of arthritis in children under the age of 16.13 Approximately 10,000 children and teens live with arthritis in Canada.14

"Merck is committed to providing Canadians with more therapeutic choices for patients and their treaters," says AnnA Van Acker, President, Merck Canada. "BRENZYS adds to Merck's portfolio of treatments for dermatological and inflammatory immune diseases and can help improve quality of life for patients living with psoriasis, psoriatic arthritis or juvenile idiopathic arthritis, as well as rheumatoid arthritis and ankylosing spondylitis."

About BRENZYS

BRENZYS is a biosimilar biologic drug (biosimilar)15 and authorized based on its similarity to ENBREL, which is already approved for use for PsO, PsA and JIA in Canada.16 A biosimilar is a biologic drug that is highly similar to a biologic drug already authorized for sale.17 Biosimilars are assessed and approved by Health Canada against the same meticulous standards used to ensure the quality, efficacy and safety of all other biologic drugs.18 Biosimilars provide patients more treatment options to help manage their disease and symptoms.

In addition to its use for the treatment of JIA, PsO and PsA, BRENZYS was first approved by Health Canada in 2016 for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adults and ankylosing spondylitis (AS).19 It is administered by an injection under the skin and should be used under the guidance and supervision of a physician.20

Clinical efficacy and safety studies have been conducted in patients with rheumatoid arthritis to demonstrate clinical comparability between BRENZYS and ENBREL. The extrapolation of these data to support uses of BRENZYS in ankylosing spondylitis is based on the demonstrated comparability, in terms of product quality, non-clinical, human pharmacokinetic and clinical characteristics. Randomized clinical trials have not been conducted to compare BRENZYS to Enbrel in patients with psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, juvenile idiopathic arthritis and pediatric psoriasis.21

The most common expected adverse reactions with BRENZYS are infections, injection site reactions and headaches. It should not be administered to patients with or at risk of sepsis. BRENZYS contains a Boxed Warning to alert health care professionals and patients about an increased risk of serious infections including tuberculosis and infections caused by bacteria, viruses or fungi that have spread throughout their body. The Boxed Warning also notes that malignancies, sometimes fatal, have been reported in children and teenage patients who started using TNF-blocking agents, including etanercept, at less than 18 years of age.22

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals including cancer, infectious diseases such as HIV and Ebola and emerging animal diseases as we aspire to be the premier research-intensive biopharmaceutical company in the world.

In Canada, Merck markets a broad range of vaccines, pharmaceutical and animal health products and is one of the top R&D investors in Canada, with investments totaling $89 million in 2019 and more than $1.3 billion since 2000. Based in Kirkland, Qubec, Merck employs approximately 650 people across the country. For more information about our operations in Canada, visit http://www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2017 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Please see the product monograph for BRENZYS (etanercept injection) at:

https://www.merck.ca/static/pdf/BRENZYS-PM_E.pdf

References

1 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

2 Psoriasis. Canadian Dermatology Foundation. 2020.

3 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis

4 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

5 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

6 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

7 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

8 Psoriasis. Canadian Dermatology Foundation. 2020.

9 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis

10 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

11 Symptoms. Canadian Association of Psoriasis Patients. 2014. canadianpsoriasis.ca/index.php/en/psoriasis/81-english/psoriasis/94-symptoms#:~:text=About%2080%25%20to%2090%25%20of,with%20silvery%20scales%20on%20top

12 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

13 https://www.mayoclinic.org/diseases-conditions/juvenile-idiopathic-arthritis/symptoms-causes/syc-20374082

14 6 facts about Juvenile Idiopathic Arthritis. Montreal Children's Hospital. 2020. https://www.thechildren.com/health-info/conditions-and-illnesses/6-facts-about-juvenile-idiopathic-arthritis

15 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

16 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

17 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.

18 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.

19 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

20 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

21 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

22 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

SOURCE Merck

Company Codes: NYSE:MRK

View original post here:
BRENZYS (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis - BioSpace

Theres no right way to practice self-care. It looks different for all of usultimately, good self-care consists of whatever helps you feel cared for. That's true for psoriatic arthritis self-care tips too. For people with psoriatic arthritis, an autoimmune condition that causes psoriasis symptoms plus issues like joint pain, stiffness, and swelling, self-care can be a huge help in managing the condition.

For people with arthritis, every day needs to be a bit of a self-care day, because you have to think of yourself before you think of anything else, Tanya G., 42, who was diagnosed 11 years ago but has had symptoms of psoriatic arthritis most of her life, tells SELF. Focusing on little things that can make your life easierlike having the right tools at your desk, or a talk-to-text app that you can use to email when your hands are flaredis self-care. Learning how to take things slowly and listening to your body is also self-care, says Annelyse A., 25, who creates artwork advocating for chronic illness on her Instagram account, Resting Itch Face. Surrounding yourself with people who care and support you? Also self-care.

Self-care simply boils down to taking care of yourself, says Tanya, sometimes in the most basic ways, and on an ongoing basis: Self-care is an everyday thing.

Here, Tanya, Annelyse, and Nitika C., 39, founder and CEO of Chronicon, a platform dedicated to elevating the lives of people with chronic illness, share the self-care practices and tips that have helped them live better with psoriatic arthritis.

You have to know what self-care means for you, says Tanya. For me, that means being prepared for bad days. Bad days will happen; theyre not going to magically go away. So what is going to be in my house that is going to support me on a bad day? For Tanya, this means having a few things on hand: bath bombs, a good book on her Kindle, and medication she can use during a serious flare. It means thinking ahead and doing laundry on a good day so her compression socks are clean and ready when she needs them. And, of course, it also means having her favorite comfort foods, like chocolate, on hand.

When I was really at my sickest in my 20s, I think the biggest thing that helped me was mindfulness, Nitika tells SELF. I didnt grow up knowing about it, but it really changed me. It made me feel like I could really help myself feel better on the inside, which I saw helped how I was feeling on the outside. Nitika says she noticed her stress levels go down when she learned how to stay present instead of letting the pain take over. Tanya also meditatesshe swears by the Calm app, specifically a training program the app has for pain management. I do it probably at least once a month to remember the steps for how to breathe through pain, she says.

While that laughter is the best medicine doesnt necessarily apply when it comes to chronic pain, it can still make a difference in how youre coping. Ive always known that friends and laughter were incredibly important, Nikita says. When she was younger and unable to get out of the house easily, she would call a friend to just talk. Not about psoriatic arthritis or the pain she was in, but just 20-something things like a cute guy or a weird dream or something that happened on a TV show. I remember that being so helpful. And even in times when that wasn't enough because maybe I was in so much pain or had a really big flare-up, I started getting into the habit of looking at funny videos online, like Carpool Karaoke, she adds. Its stupid and fun and makes me so happy, and its free.

For Tanya, self-care means making sure to surround herself with people who know that she may have to cancel plans and wont judge her or get angry at her for it. On the flip side, that also means distancing herself from people who just dont get itor rather, those who dont even attempt to understand. There are some people who don't get it who want to get it and say hurtful things because they just don't get it but want to be there for you. And then there are people who just think youre faking, and those are the people you have to distance yourself from, Tanya says.

Go here to read the rest:
9 Psoriatic Arthritis Self-Care Tips for Anyone With the Condition - Self

Arthritis is a common condition among dogs. It causes a lot of pain, and no pet parent wants their cuddle buddy to suffer! Read on to know how you can help your pooch cope with arthritis and its symptoms.

Arthritis in dogs can cause pain in the joints and affect dogs as they age. The most common type of arthritis that affects dogs is osteoarthritis, which usually affects seniors and large breeds. It is the inflammation of the joints caused by the deterioration of cartilage. Common symptoms of arthritis include limping, difficulty in moving, spinal issues, irritability, and tiredness. Some of the most common breeds that get affected by the problem include Labradors, Retrievers, German Shephard and Rottweilers.

Watching your furry friend suffering will definitely make you upset, and you might look for ways to curb the disease or decrease the pain. Well, there is no cure for the disease, but there are ways that can help to improve its symptoms. As a pet parent, you must help your canine to cope with the painful condition.

1- Arthritis is a common condition that affects overweight dogs. Helping them lose weight might decrease the pain and improve their symptoms.

2- Make them do gentle, controlled and low impact exercises that will keep them moving. It will help relieve the pain.

3-You can also invest in ramps to help your dog climb up the stairs, on the bed, stairs, or cars.

4-Regular massage will also help your pooch feel better. It will improve circulation, help them relax, lower blood pressure and reduce stress. You can gently massage your dogs joints, or seek professional help.

5- Invest in an orthopaedic dog bed that will support your quadrupeds joints and bones and help them relax.

6- Heating pads are another option that can help provide some relief. It will promote muscle relaxation, stimulate acupuncture points, and heal injuries.

ALSO READ:Want to know about your personality? Your pets can tell it all

x Your comment has been submitted to the moderation queue

Here is the original post:
Arthritis in Dogs: Heres how to help your canine cope with it - PINKVILLA

In her weekly column, Bradford West Gwillimbury licensed nutritionist Nonie De Long shares a few herbs you need in your medicine cabinet if you live with arthritis

Dear Nutritionist,

I suffer from arthritis and have to have a lot of medication for pain. I take daily NSAIDs and Im worried. I get horrible constipation and stomach pain and I notice the joint pain has started to get resistant. Ive had to go higher in my dose, which worries me. My rheumatoid arthritis started fiveyears ago. I was told it only gets progressively worse. I know theres no known cure but would you know of any safe and natural treatment that can help with the pain so I could reduce the amount of NSAIDs I take? Thank you for your column!

Thank you!Melaena from Barrie

Dear Malaena,

I love these difficult questions, keep them coming!

You are going to be on cloud 9, Malaena, because I know holistic therapies that both help with the pain of RH arthritis and ones that help manage it long-term. This is because I used to suffer from it. But not anymore.

You see, when I was 19 I was diagnosed with it. I had gotten mononucleosis from working at a cafe and handling all the dishware. When my immune system was taken out with mono I developed painful swelling in all my joints. I mean every joint - even my toes! My knees were at least 3x their normal size! I was at first diagnosed with water on the knee then had tests for rheumatoid factor (RF) and was diagnosed with migratory rheumatoid arthritis. They said it was migratory because after the initial flare up it moved around from joint to joint, often taking out several at once.

I was so ceased up I had to manually unlock my joints after sleeping because they would lock up in the position I had been in. It was excruciating. Ladies, think of the pain of labour and multiply that by 10! Its unbelievable how painful it is! Once I got moving I had to crawl to the bath - probably 3x a day - to soak in hot water. It was the only thing that gave me any relief.

All I could do was eat boiled noodles, drink hot chocolate, crush tylenol 3, bathe, and sleep. I moved like a zombie and a friend who saw me during that time commented that I looked like I had aged 30 years.

Fast forward to today and I rarely have a flare up and know exactly how to treat it if I do. But the solution came in increments over the years. Let me explain.

First, let me back up. During the flare up I had a manual car and couldnt drive because my knees couldnt handle it. This was before cell phones so I didnt have one of those either. And I had lost my job so I didnt have a landline either. I lived in the country and my then partner left. So I eventually ran out of food and hot chocolate. When I did I was forced to water fast. I now know water fasting is extremely beneficial for overcoming inflammation but I didnt know that then. I just knew that spontaneously started to get better. Within threedays of no food (toxins) I was feeling much much improved. Enough to drive and stop the T3. Once I did that, I never got so bad again.

But every year when I returned to school and rather frequently after parties the RA would flare up - sometimes for days and sometimes for months. It mostly affected my knees but also my elbows and shoulders and every time I had to wake to ceased joints I would get that familiar terror... wondering if it was coming back again. I lived in fear. Doctors and specialists could not explain the coming and going symptoms.

Then my stepmother made a discovery.

My father had had a triple bypass and had to switch to decaf for his recovery. Because of that she switched, too. She reported to me that her arthritis was much improved. Did I want to try it for mine? Well, it was easy enough to do so I switched to decaf all the time. Immediately I got about an 80 per centimprovement. So I ditched the caffeine altogether for a couple weeks and the RA went away entirely. I was flabbergasted. Everything started to make sense.

When I returned to school or went to functions I invariably drank coffee that I would not drink at home. Or eat a little chocolate something. I didnt have these in my home. I drank decaf at home because I knew the caffeine made me jittery. So when I drank regular coffee at school or functions I would get a flare up. I also realized why it got so bad with my migraines. My migraine medicine has caffeine in it. Guess what else does? T3s.

I had been living on hot chocolate and T3s when I had my worst flare up!

Today I have to be careful how much caffeine I have. But it took me years to be able to tolerate it at all. I had to work on my liver and remove low grade food intolerances from my diet. Still, if I overdo caffeine, dairy, and wheat I am down for a couple days. You could say those are my kryptonite.

Every person Ive treated for RA has serious underlying food intolerances and is sensitive to some degree to alcohol and caffeine. They usually also have some issues with their blood and digestion. Aside from telling you to switch to swiss water decaf and throw out the teas and chocolate immediately, I want you to avoid all alcohol and talk to your doctor about replacing any medications that have caffeine for a trial to see if it benefits you. I suggest you get food intolerance testing by a professional and figure out which foods trigger you. This is essential in the long run.

Next I suggest a few herbs to help with pain relief. NSAIDs are particularly damaging not only to the lining of the stomach and digestive system but to the gut biome, and this causes an increase in inflammation over time! That is not what we want.

Turmeric and the curcumin from it are both extremely beneficial in helping joint pain. They thin the blood, though, so a licensed physician needs to supervise use if you are taking blood thinners. The good news is it can work just like low dose aspirin without the side effects. But again, do not make changes without talking to a doctor to oversee this if you take meds for your blood. You can get this supplement in capsule form and you can add powdered turmeric to your food. Most potent may be the liposomal form, but it would need to be consumed with food. You can also use the root, which looks like a bright orangey yellow ginger - to fresh juices for added benefit.

The reason NSAIDs damage the stomach lining is they down regulate prostaglandins - of which some cause pain and some protect against pain and protect tissues like the stomach lining. We can effectively increase the beneficial prostaglandins by adding quality krill or cod liver or omega 3 fish oil into the diet as a supplement in therapeutic quantities (again taken with meals) and adding sardines and salmon (with skin and bones) into the weekly diet. You would be amazed how many cool recipes there are for sardines and canned salmon on the internet. Do a search and try something new!

In addition, using herbs to help your liver work better helps address this issue at the root. I use milk thistle, dandelion, and alpha lipoic acid in high doses with custom herbal tinctures for clients with these issues. Professional supervision is best for any high dose of supplements for any length of time.

I also recommend a liquid diet to take strain off of the digestive system and ensure all nutrients are being absorbed optimally until the bodys inflammation is under control. Bone broth is particularly soothing to a weak digestive system. I also recommend smoothies with quality protein and collagen peptides to help nourish without producing inflammation. This has been very effective in a number of clients in reducing pain.

Another remedy for pain that is incredible and simple is capsaicin cream. Its made from the active ingredient in chilli peppers and helps reduce the transmission of pain signals in the nerves. It can be really helpful for rubbing on the site of pain and is very safe - as long as you use gloves to apply it and dont rub your eyes after!

Lastly, homeopathics that fit your specific situation are essential if you want to turn the problem around permanently. But homeopathic remedies applied without knowledgeable dietary intervention do not produce the same results in clients, in my experience. Nutrition is the foundation of the inflammatory response in the body.

I hope this helps your pain, Malaena, and invite you to reach out to address the arthritis more deeply together.

As always, if you have your own health/nutrition questions, dont hesitate to send me an email at nonienutritionista@gmail.com. Readers can find out more about my work and sign up for my newsletter at hopenotdope.ca.

Namaste!Nonie Nutritionista

See the original post here:
If you have arthritis, here are some ideas that could help - BradfordToday

Patients with lifelong psoriatic arthritis are required to undergo treatments for prolonged periods of time. Furthermore, the higher burden of co-morbidities in the elderly population has the potential of complicating treatment course.

A new study presented at the Clinical Congress of Rheumatology (CRR) East 2020 demonstrated that treatment with ustekinumab resulted in similar efficacy and safety profiles for both age populations.

Ustekinumab specifically targets the shared p40 subunit of Interleukin (IL)-12 and IL-23. The treatment is indicated for adult patients with active psoriatic arthritis.

A team led by Elke Theander, MD, PhD, Medical Advisor of Rheumatology, Janssen Pharmaceutica, conducted a post-hoc analysis of the PsABio Study with a specific focus on comparing treatment outcomes in patients aged <60 (n = 336) and 60 (n = 102) years.

The investigators in the original study had recruited 930 patients and assigned about half to receive ustekinumab as 1st, 2nd, or 3rd line of treatment.

They then measured effectiveness using components of the American College of Rheumatology (ACR) response criteria in addition to the clinical disease activity index for psoriatic arthritis (cDAPSA) and minimal disease activity (MDA).

In the post-hoc analysis, reported mean age within the older population was 67.3 years; in the younger population, mean age was 46.1.

As noted by Theander and colleagues, both groups had similar baseline characteristics.

However, the older population had a longer psoriatic arthritis disease duration as well as a higher proportion with a history of cardiovascular disease and corticosteroid use.

Following 6 months of treatment with ustekinumab, the two subpopulations reported similar changes from baseline in components of the ACR response criteria.

Additionally, 52.2% of patients <60 years achieved cDAPSA low disease or remissioncompared with 42.9% in the 60 years group.

Mean cDAPSA was -14.4 (95% CI, -16.5 to -12.2) for the younger patients and -12.6 (95% CI, -16.1 to -9.1) for the older patients.

Furthermore, 30.0% and 20.3% of the younger and older populations, respectively, achieved MDA.

Up to 18.5% of patients <60 years experienced 1 adverse eventsversus 20.0% percent in those 60 years.

Other safety measures1 serious adverse events and withdrawal of treatment due to adverse eventswere similarly comparable between the groups.

In a real-world setting, no clinically meaningful differences were observed in the effectiveness and safety of ustekinumab treatment in PsA patients 60 years or older compared with those younger than 60, Theander and team wrote.

The study, "Effectiveness and Safety of Ustekinumab in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study: A Post-hoc Analysis Comparing Elderly to Younger Patients," was presented at CCR East 2020.

Read the original here:
Ustekinumab Safe and Efficacious in Young and Elderly Patients with Psoriatic Arthritis - MD Magazine

Arthritis is a general term for more than 100 types of joint pain or joint disease. However, osteoarthritis and rheumatoid arthritis are the two most common types of arthritis. Common arthritis joint symptoms include swelling, pain, stiffness and decreased range of motion.

These symptoms can greatly diminish a person's quality of life by making even simple tasks trying.

Unfortunately, there's no cure for arthritis, but there are many treatments that can help to alleviate symptoms.

Research has found a number of natural remedies that reduce the inflammation associated with arthritis.

Stinging nettle, which can be processed into supplements, dried, freeze-dried or cooked, appears to boast anti-inflammatory properties.

READ MORE:Best supplements for arthritis: The top three supplements to help ease painful joints

Stinging nettle packs a variety of compounds that may reduce inflammation, research suggests.

In animal and test-tube studies, stinging nettle reduced levels of multiple inflammatory hormones by interfering with their production.

In human studies, applying a stinging nettle cream or consuming stinging nettle products appeared to relieve inflammatory conditions, such as arthritis.

For instance, in one 27-person study, applying a stinging nettle cream onto arthritis-affected areas significantly reduced pain, compared to placebo treatment.

DON'T MISSBed bugs: The three different warning smells indicating you may have an infestation[INSIGHT]Hair loss treatment - Dr Sara explains the best type of shampoo to stimulate hair growth[ADVICE]Bowel cancer: Smelly warning sign which could indicate early diagnosis of deadly condition[INSIGHT]

In another study, taking a supplement that contained stinging nettle extract significantly reduced arthritis pain.

Additionally, participants felt they could reduce their dose of anti-inflammatory pain relievers because of this capsule.

If your arthritis is painful, you may not feel like exercising. However, being active can help reduce and prevent pain.

According to the NHS, regular exercise can also:

A growing body of research supports the benefit of aerobic and strengthening exercise in alleviating arthritis, according to a literature review.

It suggested that the intensity level of the aerobic exercise should be moderate to hard and exercise be performed three times weekly for a duration of 30 to 60 minutes.

Any type of exercise which makes you breathe deeper and faster can be aerobic.

Examples of low-impact aerobic exercises that are easier on your joints include walking, bicycling and swimming.

Exercise also aids weight loss, which is crucial for managing arthritis symptoms.

The NHS explains: "Too much weight places excess pressure on the joints in your hips, knees, ankles and feet, leading to increased pain and mobility problems."

To help you maintain a healthy weight and alleviate your arthritis symptoms, it's very important to eat a healthy, balanced diet, says the health body.

Your diet should consist of a variety of foods from all five food groups.

These are:

See the rest here:
Arthritis treatment: Apply this herbal cream to significantly reduce pain - Express